Lipid Disorders Management Strategies (2024) in Prediabetic and Diabetic Patients

Laura Gaita,Bogdan Timar,Romulus Timar,Zlatko Fras,Dan Gaita,Maciej Banach
DOI: https://doi.org/10.3390/ph17020219
IF: 4.6
2024-02-08
Pharmaceuticals
Abstract:Dyslipidaemia is a modifiable risk factor commonly associated with diabetes mellitus and prediabetes, with a major impact on the early development of atherosclerotic cardiovascular disease. Various studies have tried to identify the key treatment targets, their optimal values according to patients' CV risk, and the most efficient yet safe therapeutic agents which, alongside lifestyle changes, would improve lipid levels and reduce cardiovascular mortality and morbidity. Currently, there are multiple pharmacologic options that can be used in the management of dyslipidaemia, such as statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, n-3 polyunsaturated fatty acids or fibrates, to name only a few, while many other are under development. In the current setting of a continuously increasing population of patients with metabolic disorders, this review aims to summarise current knowledge regarding lipid disorders and the recommendations of recent guidelines in treating dyslipidaemia in patients with diabetes mellitus or prediabetes.
pharmacology & pharmacy,chemistry, medicinal
What problem does this paper attempt to address?
The problem that this paper attempts to solve is: how to effectively manage lipid disorders in pre - diabetic and diabetic patients in order to reduce the risk of cardiovascular disease (CVD). ### The specific content is summarized as follows: 1. **Background and problems**: - Lipid disorders (such as hypercholesterolemia, hypertriglyceridemia, etc.) are important modifiable risk factors for cardiovascular diseases. - The risk of cardiovascular diseases in diabetic and pre - diabetic patients is significantly increased, so more effective lipid management strategies need to be developed for these populations. - The paper focuses on the treatment goals of lipid disorders, tools for assessing cardiovascular risk, and currently available drug treatment methods. 2. **Research objectives**: - Summarize the current knowledge on lipid disorder management in diabetic and pre - diabetic patients. - Recommend the treatment goals and methods proposed in the latest clinical guidelines. - Provide personalized treatment suggestions for patients with different levels of cardiovascular risk. 3. **Key scientific questions**: - How to set appropriate treatment goals according to the individual characteristics of patients (such as cardiovascular risk, metabolic status, etc.)? - Which drugs or lifestyle interventions can most effectively reduce the lipid - disorder - related risks in diabetic and pre - diabetic patients? - Are there any new treatment methods or drugs that can further improve the prognosis of patients? 4. **Main areas involved**: - **Cardiovascular disease prevention**: Reduce the incidence of cardiovascular events by controlling blood lipid levels. - **Drug treatment**: Including statins, ezetimibe, bempedoic acid, PCSK9 inhibitors, etc. - **Lifestyle intervention**: Diet adjustment, increasing the amount of exercise, smoking cessation, etc. 5. **Core formulas and indicators**: - **LDL - C target values**: - Very high cardiovascular risk: <1.4 mmol/L (55 mg/dL), and at least 50% reduction from the initial level. - High cardiovascular risk: <1.8 mmol/L (70 mg/dL), and at least 50% reduction from the initial level. - Moderate cardiovascular risk: <2.6 mmol/L (100 mg/dL). - **Non - HDL - C target values**: - Very high cardiovascular risk: <2.2 mmol/L (85 mg/dL). - High cardiovascular risk: <2.6 mmol/L (100 mg/dL). - Moderate cardiovascular risk: <3.4 mmol/L (130 mg/dL). - **Other indicators**: - Triglyceride (TG): <1.69 mmol/L (150 mg/dL). - High - density lipoprotein cholesterol (HDL - C): >1 mmol/L (40 mg/dL) for men, >1.29 mmol/L (50 mg/dL) for women. 6. **Conclusion**: - Managing lipid disorders in diabetic and pre - diabetic patients requires comprehensive consideration of the specific situation of patients, including cardiovascular risk, metabolic status, etc. - The combination of lifestyle intervention and drug treatment is the best strategy. - New drugs (such as PCSK9 inhibitors, siRNA technology) provide more options for refractory cases. Through the above analysis, the paper aims to provide scientific basis for clinicians to help them develop more effective lipid disorder management plans, thereby reducing the cardiovascular disease risk in diabetic and pre - diabetic patients.